
## **Science Resistance to Antibiotics**

## FRONTIERS IN BIOTECHNOLOGY

NEWS REPORTS Reviving the Antibiotic Miracle?	360
Funding Crunch Hobbles Antibiotic Resistance Research	362
Resistance a European Problem, Too	363
Hungary Sees an Improvement in Penicillin Resistance	364
Search for Sepsis Drugs Goes on Despite Past Failures	365
Sepsis: An Immune System Gone Haywire	366
<b>POLICY FORUM</b> Infectious Disease Surveillance: A Crumbling Foundation <i>by R. L. Berkelman et al.</i>	368
PERSPECTIVES Human Mycoses: Drugs and Targets for Emerging Pathogens by N. H. Georgopapadakou and T. J. Walsh	371
Ubiquitous Natural Antibiotics by J. E. Gabay	373
<b>ARTICLES</b> Inactivation of Antibiotics and the Dissemination of Resistance Genes by J. Davies	375
Prevention of Drug Access to Bacterial Targets: Permeability Barriers and Active Efflux <i>by H. Nikaido</i>	382
Resistance to Antibiotics Mediated by Target Alterations by B. G. Spratt	388



For several years now, medical microbiologists have been tracking an alarming trend. With increasing frequency, they've been finding that antibiotics that formerly killed bacterial pathogens with ease were becoming ineffective—the result of resistance mechanisms developed by the ever-crafty bacteria. This raised the specter of what one researcher calls the "post-microbial era"—a return to the bad old days when a simple infection could turn life-threatening for lack of effective treatment. *Science* surveyed the widening scope of this resistance problem in several articles published on 21 August 1992, and now returns to the topic with a special issue produced by the Editorial and News Departments.

This issue picks up where the earlier one left off. Because an appreciation of the mechanisms through which bacteria develop antibiotic resistance is critical to a rational approach to the design of effective new drugs, it takes a much more detailed look at research aimed at understanding those mechanisms, as well as at how that information is being used—or not used—by the drug industry. Other drug exploratory efforts, for fungal diseases and sepsis, an often fatal consequence of infection, also come in for attention, as does the critical issue of funding for research on antibiotic resistance. And finally, because combating the surge in antibiotic-resistant microbes requires not just research but the tracking of new and existing outbreaks, there's consideration of what's needed on the surveillance front. Only through a multi-pronged effort will it be possible to stave off the post-microbial era.

-Gilbert J. Chin and Jean Marx

SCIENCE • VOL. 264 • 15 APRIL 1994